Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oral Salmonella msbB Mutant as a Carrier for a Salmonella-Based Vaccine for Prevention and Reversal of Type 1 Diabetes.

Frontiers in immunology - 1 Jan 2021

Cobb Jacob, Rawson Jeffrey, Gonzalez Nelson, Hensel Michael, Kandeel Fouad, Husseiny Mohamed I

Abstract excerpt

A therapy that includes an oral vaccine for type 1 diabetes (T1D) using live attenuated Salmonella MvP728 (ΔhtrA/ΔpurD), cytokines (IL10 and TGFβ) and preproinsulin (PPI) antigen in combination with a sub-therapeutic dose of anti-CD3 mAb was developed by our team. The vaccine combination therapy reduced insulitis and prevented and reversed diabetes in non-obese diabetic (NOD) mice. Here, we show the effectiveness...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acyltransferases
Share to Administration, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD3 Complex

Share to Mice, Inbred NOD

Share to RAW 264.7 Cells

Share to Salmonella

Share to Vaccines, Attenuated

Share to Vaccines, DNA

Source

Open in PubMed Open full text

Identifiers

PMID: 34108968
DOI: 10.3389/fimmu.2021.667897
PMCID: PMC8181392

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oral Salmonella msbB Mutant as a Carrier for a Salmonella-Based Vaccine for Prevention and Reversal of Type 1 Diabetes.PMID 34108968Read ↗

Reversal of New Onset Type 1 Diabetes by Oral Salmonella-Based Combination Therapy and Mediated by Regulatory T-Cells in NOD MiceSemantic proximity Read ↗

A Gut Microbial Peptide and Molecular Mimicry in the Pathogenesis of Type 1 DiabetesSemantic proximity Read ↗

Strategies for Enhancement of Live-Attenuated Salmonella-Based Carrier Vaccine ImmunogenicitySemantic proximity Read ↗

Live attenuated Salmonella: a paradigm of mucosal vaccinesSemantic proximity Read ↗

Yersinia enterocolitica ghost with msbB mutation provides protection and reduces proinflammatory cytokines in mice.Semantic proximity Read ↗

Evaluation of Salmonella enterica serovar Typhimurium TTSS-2 deficient fur mutant as safe live-attenuated vaccine candidate for immunocompromised mice.Semantic proximity Read ↗

Outer membrane vesicles from genetically engineered Salmonella enterica serovar Typhimurium presenting Helicobacter pylori antigens UreB and CagA induce protection against Helicobacter pylori infection in miceSemantic proximity Read ↗

Escherichia coli LTB26 mutant enhances immune responses to rotavirus antigen VP8 in a mouse model.Semantic proximity Read ↗

Type 2 diabetes increases susceptibility to invasive <i>Salmonella</i> Typhimurium despite butyrate supplementationSemantic proximity Read ↗

Pathogenicity island 2 mutants of Salmonella typhimurium are efficient carriers for heterologous antigens and enable modulation of immune responses.Semantic proximity Read ↗

Bacillus subtilis comes of age as a vaccine production host and delivery vehicleSemantic proximity Read ↗

Orally Antigen-Engineered Yeast Vaccine Elicits Robust Intestinal Mucosal ImmunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.